Hotdogs and colon cancer: Risk or fear-mongering? CHICAGO -- A new TV commercial shows kids eating hotdogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
FDA Approves Nplate for Long-Term Treatment of Adult Chronic ITP Amgen Inc.has announced that the FDA has approved Nplate(TM) (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non-splenectomized adults with chronic...
Stark Matters: Frankly, commercial about colon cancer is hogwash, baloney Recent Headlines This 'N' That: 2008 election isn't about them, it's about you Worrying about one's diet is American as hot dogs and apple pie, but now hot dogs themselves are under attack.Can apple pie be next?
In case you missed it, a...
Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
Group Stirs Controversy With New Hot Dog-Cancer Ad Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon...
Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
What next? Apple pie?Latest TV attack ad links hot dogs to colon cancer But the boy doesn't have cancer.Neither do two other kids in the ad who claim to be afflicted.
The commercial's pro-vegetarian sponsors say it's a dramatization that highlights research linking processed meats, including hot dogs, with...
Group Stirs Controversy With New Hot Dog-Cancer Ad Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon...
Ad attacks hot dogs, says it has link to colon cancer CHICAGO -- A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
Group Stirs Controversy With New Hot Dog-Cancer Ad CHICAGO (AP) A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boy's haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' It's a startling revelation in an ad that...
New attack ad on TV, but this one targets hot dogs (AP) CHICAGO - A new TV commercial shows kids eating hot dogs in a school cafeteria and one little boys haunting lament: 'I was dumbfounded when the doctor told me I have late-stage colon cancer.' Its a startling revelation in an ad that...
Ahead of the Bell: Citi rates Incyte 'Buy' NEW YORK - A Citi Investment Research analyst began coverage of Incyte Corp.with a 'Buy' rating late Tuesday, predicting success for the drug developer's prospective myelofibrosis treatment and noting its deep slate of product candidates....
Ahead of the Bell: Citi rates Incyte 'Buy' Analyst places 'Buy' rating on Incyte on potential sales for INCB18424 and solid pipeline NEW YORK (AP) -- A Citi Investment Research analyst began coverage of Incyte Corp.with a 'Buy' rating late Tuesday, predicting success for the drug...
Ahead of the Bell: Citi rates Incyte 'Buy' A Citi Investment Research analyst began coverage of Incyte Corp.with a 'Buy' rating late Tuesday, predicting success for the drug developer's prospective myelofibrosis treatment and noting its deep slate of product candidates.
Lucy Lu...
Analyst places 'Buy' rating on Incyte on potential sales for INCB18424 and solid pipeline NEW YORK (AP) - A Citi Investment Research analyst began coverage of Incyte Corp.with a 'Buy' rating late Tuesday, predicting success for the drug developer's prospective myelofibrosis treatment and noting its deep slate of product...
Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma By Cormac Sheridan BioWorld International Correspondent Novosom AG in-licensed from Isis Pharmaceuticals Inc.the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis...
Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma Cormac Sheridan, BioWorld Today CorrespondentNovosom AG in-licensed from Isis Pharmaceuticals Inc.the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ...
Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma Cormac Sheridan, BioWorld Today Correspondent Novosom AG in-licensed from Isis Pharmaceuticals Inc.the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ...
FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts -- The U.S.Food and Drug Administration today approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding....
Amgen's Nplate gets US FDA nod for adult chronic ITP Amgen Inc.announced that the United States Food and Drug Administration (FDA) has approved Nplate (romiplostim), the first and only platelet producer for the treatment of thrombocytopenia in splenectomized (spleen removed) and non...
FDA approves Amgen's Nplate to treat adult chronic ITP Amgen has said that the US Food and Drug Administration (FDA) has approved Nplate (romiplostim) to treat chronic immune thrombocytopenic purpura (ITP).A prepared company release said Nplate is the first and only platelet producer for the...
FDA approves Amgens Nplate to treat adult chronic ITP Amgen has said that the US Food and Drug Administration (FDA) has approved Nplate (romiplostim) to treat chronic immune thrombocytopenic purpura (ITP).A prepared company release said Nplate is the first and only platelet producer for the...
FDA Approves Bone Marrow Stimulator For Immune-Related Low Platelet Counts The U.S.Food and Drug Administration today approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.
FDA Approves First Bone Marrow Stimulator to Treat Immune-Related Low Platelet Counts The U.S.Food and Drug Administration today approved Nplate (romiplostim), the first product that directly stimulates the bone marrow to produce needed platelets in patients with a rare blood disorder that can lead to serious bleeding.
